Morningstar | The leading position of IQVIA is expected to provide strong and steady long-term growth.
IQVIA (formerly QuintilesIMS) is the result of the merger of Quintiles, the leading provider of late-stage contract research, and IMS Health, the dominant player in healthcare data and analytics. The combined firm’s unparalleled scale and reputation support its well-entrenched position in outsourced drug research, development, and commercialization, and we believe IQVIA will remain the leader in this niche space for the foreseeable future.The company’s global scale and comprehensive data set enhance its ability to attract and retain healthcare customers throughout the life cycle of a drug product. The IMS business compiles data from over 100,000 sources, including pharmacies, medical claims, and electronic health records, and has access to over 500 million patient records. This unmatched data set, coupled with an overlay of proprietary methodology and technology, enables clients to set informed strategies to most effectively commercialize their drugs. IMS data is well-embedded in the processes of many of its customers, which includes most large companies in the healthcare sector. As a result, the business commands a pricing premium and high retention rate of existing clients.While IQVIA’s contract research organization business is a leader in its own right--the firm’s late-stage sales are more than double the next largest competitor--unlimited access to IMS’ global patient data could help the segment more effectively source patients, design clinical trials, position their clients’ trials for the higher probability of success. Phase 3 trials usually require thousands of patients and frequently take place across many geographic locations, and IQVIA is one of the few CROs with the global infrastructure to win these contracts. The firm's size and expertise means it works on more clinical trials than any competitor, making it the go-to partner for the most complex and expensive research projects.IQVIA Holdings is a provider of analytics, technology solutions and contract research services to the life sciences industry. The company's reportable segments are: Technology and Analytics Solutions, which provides information, technology solutions and real world solutions and services to life science clients; Research and Development Solutions, which primarily serves biopharmaceutical clients, is engaged in research and development and provides clinical research and clinical trial services; and Contract Sales and Medical Solutions, which provides contract sales to both biopharmaceutical clients and the healthcare market.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.